JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Innoviva Inc

Fermé

SecteurSoins de santé

17.55 -1.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

17.38

Max

17.8

Chiffres clés

By Trading Economics

Revenu

110M

64M

Ventes

12M

100M

P/E

Moyenne du Secteur

31.088

37.003

Marge bénéficiaire

63.508

Employés

127

EBITDA

111M

84M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+114.81% upside

Dividendes

By Dow Jones

Prochains Résultats

4 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-50M

1.1B

Ouverture précédente

18.68

Clôture précédente

17.55

Sentiment de l'Actualité

By Acuity

42%

58%

157 / 373 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 oct. 2025, 23:28 UTC

Actions en Tendance

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 oct. 2025, 23:07 UTC

Résultats

Prudential PLC 3Q New Business Profit Up 13%

30 oct. 2025, 00:00 UTC

Résultats

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 oct. 2025, 00:00 UTC

Résultats

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 oct. 2025, 00:00 UTC

Résultats

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 oct. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 oct. 2025, 23:40 UTC

Résultats

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 oct. 2025, 23:38 UTC

Market Talk

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 oct. 2025, 23:25 UTC

Résultats

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 oct. 2025, 22:51 UTC

Résultats

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 oct. 2025, 22:45 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 oct. 2025, 22:41 UTC

Résultats

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 oct. 2025, 22:41 UTC

Résultats

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 oct. 2025, 22:09 UTC

Résultats

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 oct. 2025, 22:08 UTC

Market Talk
Résultats

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 oct. 2025, 21:58 UTC

Résultats

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 oct. 2025, 21:58 UTC

Résultats

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 oct. 2025, 21:57 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 oct. 2025, 21:54 UTC

Résultats

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 oct. 2025, 21:46 UTC

Résultats

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 oct. 2025, 21:43 UTC

Résultats

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 oct. 2025, 21:43 UTC

Résultats

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 oct. 2025, 21:42 UTC

Résultats

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 oct. 2025, 21:42 UTC

Résultats

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 oct. 2025, 21:41 UTC

Résultats

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 oct. 2025, 21:41 UTC

Résultats

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 oct. 2025, 21:41 UTC

Résultats

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 oct. 2025, 21:41 UTC

Résultats

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 oct. 2025, 21:40 UTC

Résultats

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 oct. 2025, 21:39 UTC

Résultats

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

114.81% hausse

Prévisions sur 12 Mois

Moyen 38 USD  114.81%

Haut 55 USD

Bas 17 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

4 ratings

3

Achat

0

Maintien

1

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

157 / 373Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat